Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial
pathophysiological process that cannot yet be recapitulated in a single in vitro model …

The liver is critical to consider during drug development because of its central role in the
handling of xenobiotics, a process which often leads to localized and/or downstream tissue …

Primary human hepatocytes (PHHs) are commonly used for in vitro studies of drug-induced
liver injury. However, when cultured as 2D monolayers, PHH lose crucial hepatic functions …

Current gaps in drug safety sciences can result from the inability (1) to identify hazard across
multiple target organs,(2) to predict and risk assess with certainty against drug safety …

Drug-induced liver injury remains a frequent reason for drug withdrawal. Accordingly, more
predictive and translational models are required to assess human hepatotoxicity risk. This …

Background and aim The occurrence of drug induced liver injury (DILI) is the most common
reason of post-marketing withdrawals. DILI in humans is difficult to predict using in vitro …

Drug-induced liver injury (DILI) is a major clinical problem in terms of patient morbidity and
mortality, cost to healthcare systems and failure of the development of new drugs. The need …

There is a need for long‐lived hepatic in vitro models to better predict drug induced liver
injury (DILI). Human liver‐derived epithelial organoids are a promising cell source for …

Abstract Three-dimensional (3D) human tissue models/microphysiological systems (eg,
organs-on-chips, organoids, and tissue explants) model HIV and related comorbidities and …

Drug-induced liver injury (DILI) remains a major cause of drug development failure, post-
marketing warnings and restriction of use. An improved understanding of the mechanisms …